PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 10825443-2 2000 This study investigated the therapeutic applicability of using long-circulating liposome-encapsulated doxorubicin (DXR) targeted against the internalizing CD19 antigens present on human MM cells. Doxorubicin 102-113 CD19 molecule Homo sapiens 155-159 10825443-4 2000 Formulations of immunoliposomal doxorubicin (DXR-SIL[anti-CD19]) showed a higher association with, and higher cytotoxicity against, ARH77 cells than did non-targeted liposomal doxorubicin (DXR-SL) or isotype-matched controls (DXR-NSIL[IgG2a]). Doxorubicin 32-43 CD19 molecule Homo sapiens 58-62 32635973-0 2020 Anti-CD19 mAb-conjugated human serum albumin nanoparticles effectively deliver doxorubicin to B-lymphoblastic leukemia cells. Doxorubicin 79-90 CD19 molecule Homo sapiens 5-9 32635973-5 2020 Doxorubicin (DOX) was well encapsulated into the HSA-CD19 NPs to form an anticancer nanodrug DOX/HSA-CD19. Doxorubicin 0-11 CD19 molecule Homo sapiens 53-57 32635973-5 2020 Doxorubicin (DOX) was well encapsulated into the HSA-CD19 NPs to form an anticancer nanodrug DOX/HSA-CD19. Doxorubicin 0-11 CD19 molecule Homo sapiens 101-105 32635973-5 2020 Doxorubicin (DOX) was well encapsulated into the HSA-CD19 NPs to form an anticancer nanodrug DOX/HSA-CD19. Doxorubicin 13-16 CD19 molecule Homo sapiens 53-57 32635973-5 2020 Doxorubicin (DOX) was well encapsulated into the HSA-CD19 NPs to form an anticancer nanodrug DOX/HSA-CD19. Doxorubicin 13-16 CD19 molecule Homo sapiens 101-105 32635973-5 2020 Doxorubicin (DOX) was well encapsulated into the HSA-CD19 NPs to form an anticancer nanodrug DOX/HSA-CD19. Doxorubicin 93-96 CD19 molecule Homo sapiens 53-57 32635973-5 2020 Doxorubicin (DOX) was well encapsulated into the HSA-CD19 NPs to form an anticancer nanodrug DOX/HSA-CD19. Doxorubicin 93-96 CD19 molecule Homo sapiens 101-105 32635973-6 2020 DOX/HSA-CD19 was preferentially uptaken by CD19+ B-LL cell line KOPN-8. Doxorubicin 0-3 CD19 molecule Homo sapiens 8-12 32635973-6 2020 DOX/HSA-CD19 was preferentially uptaken by CD19+ B-LL cell line KOPN-8. Doxorubicin 0-3 CD19 molecule Homo sapiens 43-47 32635973-8 2020 Further, proapoptotic Bax and caspase-3 were significantly elevated, but antiapoptotic Bcl2 was reduced in DOX/HSA-CD19 treated KOPN-8 cells, indicating the activation of the apoptosis pathway by the nanodrug. Doxorubicin 107-110 CD19 molecule Homo sapiens 115-119 32635973-9 2020 By contrast, DOX/HSA-CD19 did not show affinity to CD19-monocytic cell line, U937, and did not affect its proliferation. Doxorubicin 13-16 CD19 molecule Homo sapiens 21-25 32635973-10 2020 Collectively, HSA-CD19 NPs are a kind of effective novel drug carrier, and DOX/HSA-CD19 is a promising antitumor nanodrug for the treatment of B-LL. Doxorubicin 75-78 CD19 molecule Homo sapiens 83-87 29928472-0 2018 Selection of a novel CD19 aptamer for targeted delivery of doxorubicin to lymphoma cells. Doxorubicin 59-70 CD19 molecule Homo sapiens 21-25 29928472-6 2018 An aptamer-doxorubicin complex (Apt-Dox) was also formulated, and selectively delivered doxorubicin to CD19-positive lymphoma cells in vitro. Doxorubicin 11-22 CD19 molecule Homo sapiens 103-107 29928472-6 2018 An aptamer-doxorubicin complex (Apt-Dox) was also formulated, and selectively delivered doxorubicin to CD19-positive lymphoma cells in vitro. Doxorubicin 36-39 CD19 molecule Homo sapiens 103-107 29928472-6 2018 An aptamer-doxorubicin complex (Apt-Dox) was also formulated, and selectively delivered doxorubicin to CD19-positive lymphoma cells in vitro. Doxorubicin 88-99 CD19 molecule Homo sapiens 103-107 18068849-0 2008 Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab" fragments and single chain Fv. Doxorubicin 41-52 CD19 molecule Homo sapiens 26-30 9699662-4 1998 The specific binding, in vitro cytotoxicity, and in vivo antineoplastic activity of doxorubicin (DXR) encapsulated in SILs coupled to monoclonal Ab anti-CD19 (SIL[anti-CD19]) were investigated against malignant B cells expressing CD19 surface antigens. Doxorubicin 84-95 CD19 molecule Homo sapiens 153-157 33639139-4 2021 Anti-CD19 monoclonal antibody was conjugated to PEGylated MTNs, and doxorubicin (DOX) was loaded in the nanoparticle. Doxorubicin 68-79 CD19 molecule Homo sapiens 5-9 33639139-4 2021 Anti-CD19 monoclonal antibody was conjugated to PEGylated MTNs, and doxorubicin (DOX) was loaded in the nanoparticle. Doxorubicin 81-84 CD19 molecule Homo sapiens 5-9 33639139-5 2021 The CD19-PEG-MTN/DOX nanoparticle could recognize CD19+ B-LL cell lines and induced them apoptosis, but nontoxic for the normal cells. Doxorubicin 17-20 CD19 molecule Homo sapiens 4-8 33639139-5 2021 The CD19-PEG-MTN/DOX nanoparticle could recognize CD19+ B-LL cell lines and induced them apoptosis, but nontoxic for the normal cells. Doxorubicin 17-20 CD19 molecule Homo sapiens 50-54 33639139-6 2021 Further, after treated with CD19-PEG-MTN/DOX nanoparticle, pro-apoptotic proteins Bax and Caspase-3 in KOPN 8 and NALM-6 cells were significantly upregulated, but anti-apoptotic proteins Bcl2, MCL-1, HSP 70, and BAG 3 were downregulated, which indicated the activation of the apoptosis pathway by the nanodrug. Doxorubicin 41-44 CD19 molecule Homo sapiens 28-32 33639139-8 2021 Besides, the cytotoxicity of CD19-PEG-MTN/DOX was low with good biocompatibility. Doxorubicin 42-45 CD19 molecule Homo sapiens 29-33 33639139-9 2021 Collectively, CD19-PEG-MTN/DOX is a promising antitumor nanodrug for the treatment of B-LL. Doxorubicin 27-30 CD19 molecule Homo sapiens 14-18